FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years
FibroBiologics (FBLG) CEO, O'HEERON PETE, was granted 92,410 stock options with an exercise price of $1.38 per share, expiring on May 4, 2036. The options will vest over four years, with one-quarter vesting on the one-year anniversary of the May 4, 2026 grant date, and the remainder in 36 equal monthly installments, contingent on continuous service. This transaction is a compensation grant, not a market purchase, and increases his direct derivative holdings to 92,410 options.
MAY 1·Stock Titan▲
A chronic wound trial moves closer: FibroBiologics targets first Q2 dose
FibroBiologics announced its Q1 2026 financial results, reporting a net loss of $5 million and critical progress in its clinical trials. The company completed cGMP manufacturing and site onboarding for its Phase 1/2 clinical trial for CYWC628 in diabetic foot ulcers, aiming to dose the first patient in Q2 2026. FibroBiologics also regained Nasdaq compliance and expanded its patent portfolio, while raising an additional $2.5 million net in a recent direct offering.
MAY 1·Stock Titan▼
FibroBiologics (FBLG) low cash, $5M loss and going concern risk
FibroBiologics (FBLG) reported a net loss of $5.0 million for the quarter ended March 31, 2026, with cash and cash equivalents of only $1.5 million. The company faces significant going concern risk without additional capital, despite raising $0.7 million in March and $2.5 million net in April through equity offerings. FBLG is a pre-revenu medical research company focusing on fibroblast-based therapies and is advancing several programs towards clinical trials, but also disclosed a material weakness in its internal financial controls.
